Overview
Biotech firm's Q4 collaboration revenue rose significantly yr/yr
Company reported a Q4 net loss
FDA cleared INDs for new TCR-T therapy candidates targeting CD45
Outlook
Company to share early clinical data from ALLOHA study in Q2 2026
TScan to launch pivotal trial for TSC-101 in Q2 2026
Company plans Phase 1 study of TSC-102-A01 and TSC-102-A03 in H2 2026
Result Drivers
ALLOHA TRIAL PROGRESS - Positive data from ALLOHA Phase 1 trial presented at ASH, showing favorable relapse-free and overall survival rates
FDA CLEARANCE - FDA cleared INDs for TSC-102-A01 and TSC-102-A03, expanding heme program to more patients
COHORT C ENROLLMENT - Completed enrollment in Cohort C of ALLOHA trial using commercial-ready manufacturing process
Company press release: ID:nGNX6CWCcz
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Collaboration and License Revenue | $2.57 mln | ||
Q4 Net Income | -$22.98 mln | ||
Q4 Basic EPS | -$0.18 | ||
Q4 Income From Operations | -$23.86 mln | ||
Q4 Operating Expenses | $26.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 479.7% above its March 3 closing price of $1.04
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)